Albireo Reports Positive Topline Data from Phase 3 Trial of Bylvay® (odevixibat) in Alagille Syndrome
11 oct. 2022 07h00 HE
|
Albireo Pharma, Inc.
Highly statistically significant improvement in pruritus primary endpoint (p=0.002)Significant reductions in key secondary endpoint of serum bile acid levels (p=0.001)Substantial improvements in...
Albireo to Showcase New Data at AASLD The Liver Meeting® 2022
05 oct. 2022 08h30 HE
|
Albireo Pharma, Inc.
– Seven abstracts accepted, including one oral presentation highlighting long-term data demonstrating Bylvay® (odevixibat) durable efficacy in patients with all types of PFIC – One abstract describes...
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
27 sept. 2022 16h30 HE
|
Albireo Pharma, Inc.
BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today...
Albireo Announces $115 Million Royalty Monetization Agreement with Sagard
22 sept. 2022 08h30 HE
|
Albireo Pharma, Inc.
Upfront payment for continued clinical development and commercialization of Bylvay® Sagard to receive a mid-single digit average royalty rate on Bylvay sales No liens against Bylvay intellectual...
Albireo to Participate in Guggenheim Nantucket Therapeutics Conference
20 sept. 2022 08h00 HE
|
Albireo Pharma, Inc.
BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today...
Italian Medicines Agency Approves Reimbursed Access to Bylvay® (odevixibat) For Patients with All PFIC Types
06 sept. 2022 08h00 HE
|
Albireo Pharma, Inc.
Positive Agenzia Italiana del Farmaco (AIFA) decision provides reimbursed access to the first medicine available for the treatment of all types of PFIC, a rare and devastating disorder that affects...
L'Agenzia Italiana del Farmaco approva il rimborso di Bylvay® (odevixibat) per i pazienti affetti da tutti i tipi di Colestasi Intraepatica Familiare Progressiva (PFIC)
06 sept. 2022 08h00 HE
|
Albireo Pharma, Inc.
La decisione positiva dell'Agenzia Italiana del Farmaco (AIFA) consente l'accesso al rimborso per il primo farmaco disponibile per il trattamento di tutti i tipi di PFIC, una malattia del fegato...
Albireo to Participate in Upcoming Investor Conferences
01 sept. 2022 08h00 HE
|
Albireo Pharma, Inc.
BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today...
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
22 août 2022 17h13 HE
|
Albireo Pharma, Inc.
BOSTON, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the grant of inducement restricted...
Albireo Reports Q2 2022 Financial Results and Business Update
15 août 2022 16h05 HE
|
Albireo Pharma, Inc.
Bylvay®(odevixibat) Q2 2022 net product revenue $5.9 million, June YTD 2022 $10.5 millionAgreed Bylvay reimbursement contract in Italy and Belgium with launches planned for the fallGlobal Phase 3...